Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

A Perspective on Inherited Kidney Disease

Lessons for Practicing Nephrologists

Mathieu Lemaire and Rulan S. Parekh
CJASN December 2017, 12 (12) 1914-1916; DOI: https://doi.org/10.2215/CJN.11751017
Mathieu Lemaire
*Division of Nephrology, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada;
†Cell Biology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rulan S. Parekh
*Division of Nephrology, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada;
‡Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada
§Child Health Evaluative Sciences Programs, SickKids Research Institute, Toronto, Ontario, Canada; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • inherited kidney disease
  • Penetrance
  • Genes, Modifier
  • Kidney Diseases
  • Kidney Glomerulus
  • kidney
  • Mutation
  • Genomics

Genetic studies focused on rare kidney diseases have informed our knowledge and understanding of key kidney structures, such as glomeruli and tubules, while also identifying novel druggable targets (e.g., SGLT2 inhibitors). Recent advances in genomics have highlighted the complexity of Mendelian conditions (1). This complexity is due to allelic heterogeneity (distinct mutations on one gene produce distinct phenotypes), locus heterogeneity (mutations on distinct genes result in similar phenotypes), reduced penetrance, variable expressivity, modifier genes, and/or environmental factors.

Nephronophthisis is one of these complex diseases. There are 20 genes that cause kidney lesions within the nephronophthisis spectrum. Patients typically present with polyuria and normal-sized kidneys harboring corticomedullary cysts; most develop ESRD over time. Extrarenal abnormalities are often uncovered in the context of specific syndromes and cannot be predicted on genotype information alone. Additionally, a subset of Joubert and related syndromes, all with the same structural cerebellar lesion, presents with kidney abnormalities that resemble nephronophthisis. Although there are now 27 genes associated with Joubert syndrome, only six have been formally linked to nephronophthisis. Two articles in this issue of the Clinical Journal of the American Society of Nephrology (2,3) provide complimentary data that illustrate the complexity of genotype to phenotype landscapes for patients with nephronophthisis (2) or Joubert syndrome (3). The unique feature of these contributions is in their opposite starting points (kidney or brain involvement) and target outcomes (associated neurologic or kidney phenotypes) in the context of well defined molecular diagnoses. Both papers highlight the wide spectrum of affected organs in both conditions (2,3).

What is clear from these two studies is that the “diagnostic odyssey” (4) experienced by patients does not end with the identification of a disease-causing genotype. Systematic investigations may lead to the discovery of nonobvious phenotypes (Figure 1), suggesting that nephrologists undertake a more detailed “phenomic” approach. Data from these studies may help avoid unnecessary delays to institution of therapies by highlighting unexpected but robust genotype-phenotype associations. More importantly, these studies raise awareness about the unique attributes of a disease in range and severity. The traditional approach using textbook signs and symptoms to guide diagnosis and management is no longer sufficient (5).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The diagnostic odyssey for patients who undergo genetic testing. Patient entry into the medical system is usually triggered by the presence of obvious symptoms or an incidental finding (closed arrowheads). This dictates the extent and depth of the diagnostic odyssey that follows, which in turn, helps define the plan of care. It usually includes additional investigations that lead to the discovery of additional abnormalities (blue arrows). Genetic testing is conducted to secure a molecular diagnosis among known genes associated with the condition. Genetic results will often trigger additional diagnostic investigations that uncover additional phenotypes (red arrows). Careful analysis of all rare variants found is required to determine their pathogenic potential. The main causes of phenotypic heterogeneity are illustrated (environment, modifier genes, penetrance, and expressivity). Also represented are allelic heterogeneity (distinct mutations on one gene can produce distinct phenotypes; open arrowheads) and locus heterogeneity (mutations on distinct genes can result in similar phenotypes; stack of disease-causing mutations).

König et al. (2) report on the phenotype of 152 patients diagnosed with nephronophthisis. Disease-causing mutations were identified in 97 patients, 60% of whom were carrying NPHP1 mutations. Despite the large study, no pathogenic genotypes were found in 14 of 20 known NPHP genes. The other five genes tested were represented by a median of three patients (range, 1–6). A significant proportion of disease subtypes remains undefined with no molecular diagnosis (30% of patients). In contrast, the study by Fleming et al. (3) included 97 patients who met diagnostic criteria for Joubert syndrome and identified a pathogenic genotype in 95% of patients, implicating 20 of 27 genes associated with this condition. Routine mutation testing of new patients for all 41 distinct genes associated with either nephronophthisis or Joubert syndrome may help reduce the number of undiagnosed patients and further define the range of possible phenotypes.

König et al. (2) found that 23% of patients with NPHP1 genotypes had extrarenal phenotypes (mostly neurologic and/or ocular) compared with 66% in all other genes (mostly neurologic, ocular, and/or hepatic). Patients meeting diagnostic criteria for Joubert syndrome or related conditions were rare in the context of NPHP1 mutations (three of 60) but very common for other genes, such as NPHP6 (100%) or NPHP11 (67%) genotypes. Interestingly, in eight patients with NPHP1 mutations included in this cohort, the “obvious phenotype” that resulted in the initial referral was neurologic (Joubert syndrome and congenital oculomotor apraxia); the molecular diagnosis presumably triggered investigations, leading to the discovery of the kidney phenotype.

The study by Fleming et al. (3), however, was explicitly designed to determine the frequency of kidney involvement among patients meeting diagnostic criteria for Joubert syndrome or related conditions. This patient population is clearly distinct from that presented by König et al. (2), because only one patient had an NPHP1 mutation. Overall, the authors found significant kidney phenotypes in 30% of patients, 60% of whom had pathogenic mutations in nephronophthisis genes (NPHP1, NPHP6, NPHP8, or NPHP11). This overlap was only discovered by careful phenotyping with imaging, regardless of presenting signs and symptoms. Patients with mutations in NPHP11 were far more common in this study (25% versus 4% in the other study), which makes prevalence estimates difficult. Penetrance of the kidney phenotype for patients with NPHP11 mutations was only 50%. The spectrum of possible kidney pathologies in Joubert syndrome was likely underestimated in the past. For example, nearly 10% of patients in this cohort had an ARPKD-like phenotype, including 30% of patients with NPHP11 mutations. Whether this ARPKD-like phenotype was truly associated with Joubert syndrome was unclear, because only two kindred were previously identified: one with NPHP11 mutations. Identification of three patients with unilateral multicystic dysplastic kidneys also supports the notion that Joubert syndrome is associated with a broad spectrum of cystic kidney diseases. Importantly, none of these forms of cystic kidney diseases would have met selection criteria for the study by König et al. (2). Clinicians should actively investigate all patients with Joubert syndrome for a kidney phenotype given the high frequency found in patients with mutations in genes rarely associated with kidney disease (e.g., AHI1, INPP5E, or TMEM216).

Both studies have notable limitations. It is unclear if the new phenotypes uncovered lead to a change in clinical management. Reporting novel missense mutations usually require more careful vetting, because identification of rare variants in a gene (variants of unknown significance) does not guarantee pathogenicity, even if the correct gene (6). In addition, it is preferable to avoid including genes that are not yet established as disease causing, such as CELSR2 and KIAA0753 in Joubert syndrome (each observed in one patient). The phenotype spectrum delineated by König et al. (2) also may not be complete, because patients did not undergo systematic evaluations (e.g., brain magnetic resonance imaging not done in all patients). This has practical implications, because nearly all patients with congenital oculomotor apraxia are reclassified as having Joubert syndrome after magnetic resonance imaging (7).

Molecular diagnostic testing is rapidly changing with whole-genome sequencing on the horizon; hence, it is important for practicing clinicians to understand genetic testing. It is increasingly clear that deep phenotyping, defined as “precise and comprehensive analysis of phenotypic abnormalities” (8), is critical. We believe that physicians should take it one step further by reporting “deep patient characterizations,” a combination of detailed, multisystem phenotyping and careful assessment of genotype pathogenicity. It is also clear that larger sample sizes are necessary to better understand the genotype-phenotype dynamics that drive these heterogeneous conditions. International collaborations will only help in these rare kidney diseases to move knowledge forward. A deeper understanding of conditions with complex phenotypes will require active collaboration between various subspecialists caring for these patients. Because 30%–40% of patients with ARPKD do not have mutations in PKHD1 or DZIP1L (9), it may be informative to include the 41 genes identified in the nephronophthisis/Joubert syndrome continuum in an extended ARPKD diagnostic panel (10). Finally, physicians managing adult patients with a diagnosis of cystic disease should broaden the differential diagnoses to avoid missing a “pediatric” condition when the kidney and/or neurologic phenotypes may be mild enough to escape early diagnosis. Implementation of precision medicine in clinical nephrology, which is expected to improve diagnosis, prevention, and treatment of kidney disease, will require practicing nephrologists to have a good understanding of genetic testing and phenotyping (5).

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related articles, “Prospective Evaluation of Kidney Disease in Joubert Syndrome,” and “Phenotypic Spectrum of Children with Nephronophthisis and Related Ciliopathies,” on pages 1962–1973 and 1974–1983 respectively.

  • Copyright © 2017 by the American Society of Nephrology

References

  1. ↵
    1. Gilissen C,
    2. Hoischen A,
    3. Brunner HG,
    4. Veltman JA
    : Unlocking Mendelian disease using exome sequencing. Genome Biol 12: 228, 2011pmid:21920049
    OpenUrlCrossRefPubMed
  2. ↵
    1. König J
    , et al.: Phenotypic spectrum of 152 pediatric patients with nephronophthisis and related ciliopathies. Clin J Am Soc Nephrol 12: 1974–1983, 2017
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Fleming LR
    , Doherty DA, Parisi MA, Glass IA, Bryant J, Fischer R, Turkbey B, Choyke P, Daryanani K, Vemulapalli M, Mullikin JC, Malicdan MC, Vilboux T, Sayer JA, Gahl WA, Gunay-Aygun M: Prospective evaluation of kidney disease in Joubert syndrome. Clin J Am Soc Nephrol 12: 1962–1973, 2017
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Sawyer SL,
    2. Hartley T,
    3. Dyment DA,
    4. Beaulieu CL,
    5. Schwartzentruber J,
    6. Smith A,
    7. Bedford HM,
    8. Bernard G,
    9. Bernier FP,
    10. Brais B,
    11. Bulman DE,
    12. Warman Chardon J,
    13. Chitayat D,
    14. Deladoëy J,
    15. Fernandez BA,
    16. Frosk P,
    17. Geraghty MT,
    18. Gerull B,
    19. Gibson W,
    20. Gow RM,
    21. Graham GE,
    22. Green JS,
    23. Heon E,
    24. Horvath G,
    25. Innes AM,
    26. Jabado N,
    27. Kim RH,
    28. Koenekoop RK,
    29. Khan A,
    30. Lehmann OJ,
    31. Mendoza-Londono R,
    32. Michaud JL,
    33. Nikkel SM,
    34. Penney LS,
    35. Polychronakos C,
    36. Richer J,
    37. Rouleau GA,
    38. Samuels ME,
    39. Siu VM,
    40. Suchowersky O,
    41. Tarnopolsky MA,
    42. Yoon G,
    43. Zahir FR,
    44. Majewski J,
    45. Boycott KM; FORGE Canada Consortium; Care4Rare Canada Consortium
    : Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care. Clin Genet 89: 275–284, 2016pmid:26283276
    OpenUrlCrossRefPubMed
  5. ↵
    1. Joly D,
    2. Béroud C,
    3. Grünfeld JP
    : Rare inherited disorders with renal involvement-approach to the patient. Kidney Int 87: 901–908, 2015pmid:25651365
    OpenUrlPubMed
  6. ↵
    1. MacArthur DG,
    2. Manolio TA,
    3. Dimmock DP,
    4. Rehm HL,
    5. Shendure J,
    6. Abecasis GR,
    7. Adams DR,
    8. Altman RB,
    9. Antonarakis SE,
    10. Ashley EA,
    11. Barrett JC,
    12. Biesecker LG,
    13. Conrad DF,
    14. Cooper GM,
    15. Cox NJ,
    16. Daly MJ,
    17. Gerstein MB,
    18. Goldstein DB,
    19. Hirschhorn JN,
    20. Leal SM,
    21. Pennacchio LA,
    22. Stamatoyannopoulos JA,
    23. Sunyaev SR,
    24. Valle D,
    25. Voight BF,
    26. Winckler W,
    27. Gunter C
    : Guidelines for investigating causality of sequence variants in human disease. Nature 508: 469–476, 2014pmid:24759409
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wente S,
    2. Schröder S,
    3. Buckard J,
    4. Büttel HM,
    5. von Deimling F,
    6. Diener W,
    7. Häussler M,
    8. Hübschle S,
    9. Kinder S,
    10. Kurlemann G,
    11. Kretzschmar C,
    12. Lingen M,
    13. Maroske W,
    14. Mundt D,
    15. Sánchez-Albisua I,
    16. Seeger J,
    17. Toelle SP,
    18. Boltshauser E,
    19. Brockmann K
    : Nosological delineation of congenital ocular motor apraxia type Cogan: An observational study. Orphanet J Rare Dis 11: 104–112, 2016pmid:27473762
    OpenUrlPubMed
  8. ↵
    1. Robinson PN
    : Deep phenotyping for precision medicine. Hum Mutat 33: 777–780, 2012pmid:22504886
    OpenUrlCrossRefPubMed
  9. ↵
    1. Lu H,
    2. Galeano MCR,
    3. Ott E,
    4. Kaeslin G,
    5. Kausalya PJ,
    6. Kramer C,
    7. Ortiz-Brüchle N,
    8. Hilger N,
    9. Metzis V,
    10. Hiersche M,
    11. Tay SY,
    12. Tunningley R,
    13. Vij S,
    14. Courtney AD,
    15. Whittle B,
    16. Wühl E,
    17. Vester U,
    18. Hartleben B,
    19. Neuber S,
    20. Frank V,
    21. Little MH,
    22. Epting D,
    23. Papathanasiou P,
    24. Perkins AC,
    25. Wright GD,
    26. Hunziker W,
    27. Gee HY,
    28. Otto EA,
    29. Zerres K,
    30. Hildebrandt F,
    31. Roy S,
    32. Wicking C,
    33. Bergmann C
    : Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet 49: 1025–1034, 2017pmid:28530676
    OpenUrlCrossRefPubMed
  10. ↵
    University of Toronto: Biochemistry Department. Available at: http://biochemistry.utoronto.ca/wp-content/uploads/2017/10/Suppl-Table-1.pdf. Accessed October 23, 2017
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 12 (12)
Clinical Journal of the American Society of Nephrology
Vol. 12, Issue 12
December 07, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
A Perspective on Inherited Kidney Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Perspective on Inherited Kidney Disease
Mathieu Lemaire, Rulan S. Parekh
CJASN Dec 2017, 12 (12) 1914-1916; DOI: 10.2215/CJN.11751017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
A Perspective on Inherited Kidney Disease
Mathieu Lemaire, Rulan S. Parekh
CJASN Dec 2017, 12 (12) 1914-1916; DOI: 10.2215/CJN.11751017
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • APOL1 Kidney Risk Variants and Acute Kidney Injury in Those with COVID-19
  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Prospective Evaluation of Kidney Disease in Joubert Syndrome
  • Phenotypic Spectrum of Children with Nephronophthisis and Related Ciliopathies
  • PubMed
  • Google Scholar

Keywords

  • inherited kidney disease
  • Penetrance
  • Genes, Modifier
  • kidney diseases
  • Kidney Glomerulus
  • kidney
  • Mutation
  • Genomics

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire